Literature DB >> 14502655

Update on epidemiological aspects of progressive supranuclear palsy.

Irene Litvan1.   

Abstract

The cause of progressive supranuclear palsy (PSP), the most common form of the atypical parkinsonian disorders, is unknown. PSP is characterized by four-repeat tau aggregates in neurons (neurofibrillary tangles) and glia in specific basal ganglia and brainstem areas. A thorough literature review led us to hypothesize that genetic and/or environmental factors contribute to its development. It is likely that inheritance of the H1/H1 tau genotype represents a predisposition to develop PSP requiring other environmental or genetic factors. Less likely, a relatively rare mutation with low penetrance could contribute to the abnormal tau aggregation present in this disorder. The possible role of chemicals in the diet or occupation, hypertension, traumatic brain injury, coffee, and inflammation or oxidative injury are reviewed. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14502655     DOI: 10.1002/mds.10562

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  12 in total

1.  In vivo evaluation of white matter pathology in patients of progressive supranuclear palsy using TBSS.

Authors:  Jitender Saini; Bhavani Shankara Bagepally; Mangalore Sandhya; Shaik Afsar Pasha; Ravi Yadav; Pramod Kumar Pal
Journal:  Neuroradiology       Date:  2011-12-09       Impact factor: 2.804

2.  Magnetic resonance imaging in progressive supranuclear palsy.

Authors:  M Stamelou; S Knake; W H Oertel; G U Höglinger
Journal:  J Neurol       Date:  2010-12-22       Impact factor: 4.849

3.  Selective frontal neurodegeneration of the inferior fronto-occipital fasciculus in progressive supranuclear palsy (PSP) demonstrated by diffusion tensor tractography.

Authors:  Pia Kvickström; Bengt Eriksson; Danielle van Westen; Jimmy Lätt; Christina Elfgren; Christer Nilsson
Journal:  BMC Neurol       Date:  2011-01-26       Impact factor: 2.474

4.  Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study.

Authors:  Hee Kyung Park; Sindana Ilango; Christina M Charriez; Harvey Checkoway; David Riley; David G Standaert; Yvette Bordelon; David R Shprecher; Stephen G Reich; Deborah Hall; Benzi Kluger; Connie Marras; Joseph Jankovic; Richard Dubinsky; Irene Litvan
Journal:  Mov Disord       Date:  2018-02-20       Impact factor: 10.338

5.  Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.

Authors:  Irene Litvan; Peter S J Lees; Christopher R Cunningham; Shesh N Rai; Alexander C Cambon; David G Standaert; Connie Marras; Jorge Juncos; David Riley; Stephen Reich; Deborah Hall; Benzi Kluger; Yvette Bordelon; David R Shprecher
Journal:  Mov Disord       Date:  2016-02-08       Impact factor: 10.338

6.  A disease-specific metabolic brain network associated with corticobasal degeneration.

Authors:  Martin Niethammer; Chris C Tang; Andrew Feigin; Patricia J Allen; Lisette Heinen; Sabine Hellwig; Florian Amtage; Era Hanspal; Jean Paul Vonsattel; Kathleen L Poston; Philipp T Meyer; Klaus L Leenders; David Eidelberg
Journal:  Brain       Date:  2014-09-09       Impact factor: 13.501

7.  The economic costs of progressive supranuclear palsy and multiple system atrophy in France, Germany and the United Kingdom.

Authors:  Paul McCrone; Christine Anne Mary Payan; Martin Knapp; Albert Ludolph; Yves Agid; P Nigel Leigh; Gilbert Bensimon
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

8.  Characteristics of Nonmotor Symptoms in Progressive Supranuclear Palsy.

Authors:  Ruwei Ou; Wei Song; Qianqian Wei; Ke Chen; Bei Cao; Yanbing Hou; Bi Zhao; Huifang Shang
Journal:  Parkinsons Dis       Date:  2016-06-05

9.  Cerebrospinal fluid biomarker candidates for parkinsonian disorders.

Authors:  Radu Constantinescu; Stefania Mondello
Journal:  Front Neurol       Date:  2013-01-21       Impact factor: 4.003

10.  Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.

Authors:  Gilbert Bensimon; Albert Ludolph; Yves Agid; Marie Vidailhet; Christine Payan; P Nigel Leigh
Journal:  Brain       Date:  2008-11-23       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.